Westbourne Investment Advisors Inc. raised its position in Gilead Sciences Inc. (NASDAQ:GILD) by 0.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 44,304 shares of the biopharmaceutical company’s stock after buying an additional 255 shares during the period. Gilead Sciences accounts for approximately 3.3% of Westbourne Investment Advisors Inc.’s holdings, making the stock its 2nd largest position. Westbourne Investment Advisors Inc.’s holdings in Gilead Sciences were worth $3,696,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in GILD. Bank of Montreal Can purchased a new stake in Gilead Sciences during the second quarter valued at $427,750,000. Investec Asset Management LTD purchased a new stake in Gilead Sciences during the first quarter valued at $280,342,000. Parnassus Investments CA raised its stake in Gilead Sciences by 45.4% in the second quarter. Parnassus Investments CA now owns 8,460,484 shares of the biopharmaceutical company’s stock valued at $705,774,000 after buying an additional 2,640,284 shares during the last quarter. NN Investment Partners Holdings N.V. purchased a new stake in Gilead Sciences during the first quarter valued at $180,268,000. Finally, Beacon Investment Advisory Services Inc. raised its stake in Gilead Sciences by 9,951.3% in the second quarter. Beacon Investment Advisory Services Inc. now owns 1,653,145 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 1,636,698 shares during the last quarter. Hedge funds and other institutional investors own 77.94% of the company’s stock.
Shares of Gilead Sciences Inc. (NASDAQ:GILD) opened at 75.24 on Friday. The stock’s 50 day moving average is $78.95 and its 200-day moving average is $85.05. The company has a market cap of $99.29 billion, a P/E ratio of 6.60 and a beta of 1.10. Gilead Sciences Inc. has a one year low of $74.92 and a one year high of $111.11.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The company had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. During the same period last year, the firm earned $3.15 earnings per share. The firm’s revenue was down 5.7% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences Inc. will post $11.76 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.50%. The ex-dividend date of this dividend was Wednesday, September 14th. Gilead Sciences’s payout ratio is currently 16.56%.
GILD has been the subject of a number of research reports. Zacks Investment Research lowered shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Monday, June 13th. Jefferies Group reissued a “hold” rating and issued a $96.00 price target on shares of Gilead Sciences in a report on Sunday, June 12th. Morgan Stanley reissued a “hold” rating and issued a $103.00 price target on shares of Gilead Sciences in a report on Wednesday, June 15th. Leerink Swann reissued a “buy” rating and issued a $120.00 price target on shares of Gilead Sciences in a report on Tuesday, June 21st. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $97.00 price target on shares of Gilead Sciences in a report on Wednesday, June 29th. Ten equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $104.71.
In related news, insider John F. Milligan sold 70,000 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the completion of the sale, the insider now owns 1,128,963 shares in the company, valued at $87,765,583.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $77.63, for a total transaction of $7,763,000.00. Following the sale, the insider now owns 3,231,096 shares of the company’s stock, valued at approximately $250,829,982.48. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.